ATE529126T1 - Stabilisierte pharmazeutische peptid zusammensetzungen - Google Patents

Stabilisierte pharmazeutische peptid zusammensetzungen

Info

Publication number
ATE529126T1
ATE529126T1 AT04735873T AT04735873T ATE529126T1 AT E529126 T1 ATE529126 T1 AT E529126T1 AT 04735873 T AT04735873 T AT 04735873T AT 04735873 T AT04735873 T AT 04735873T AT E529126 T1 ATE529126 T1 AT E529126T1
Authority
AT
Austria
Prior art keywords
peptide compositions
stabilized pharmaceutical
pharmaceutical peptide
stabilized
peptide
Prior art date
Application number
AT04735873T
Other languages
English (en)
Inventor
Claus Juul-Mortensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/DK2004/000381 external-priority patent/WO2004105790A1/en
Application granted granted Critical
Publication of ATE529126T1 publication Critical patent/ATE529126T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04735873T 2003-06-03 2004-06-03 Stabilisierte pharmazeutische peptid zusammensetzungen ATE529126T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300820 2003-06-03
US47628203P 2003-06-05 2003-06-05
DKPA200400063 2004-01-19
US53848704P 2004-01-22 2004-01-22
PCT/DK2004/000381 WO2004105790A1 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions

Publications (1)

Publication Number Publication Date
ATE529126T1 true ATE529126T1 (de) 2011-11-15

Family

ID=36816397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735873T ATE529126T1 (de) 2003-06-03 2004-06-03 Stabilisierte pharmazeutische peptid zusammensetzungen

Country Status (5)

Country Link
US (1) US20060183682A1 (de)
EP (1) EP2292253A3 (de)
CN (1) CN1812808B (de)
AT (1) ATE529126T1 (de)
ES (1) ES2375056T3 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
WO2010048184A2 (en) * 2008-10-21 2010-04-29 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
EP2344519B1 (de) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminale fragmente von glucagon-ähnlichem peptid-1 (glp-1)
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2011049713A2 (en) * 2009-10-22 2011-04-28 Biodel Inc. Stabilized glucagon solutions
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
EP2729157B1 (de) * 2011-07-06 2019-01-16 The General Hospital Corporation Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt) 2012-12-21 2018-02-12 Sanofi Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
EP3080152A1 (de) 2013-12-13 2016-10-19 Sanofi Nicht-acylierte exendin-4-peptidanaloga
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
WO2021219710A1 (en) * 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
CN115960201B (zh) * 2021-10-09 2023-08-11 合肥天汇生物科技有限公司 一种glp-1类似物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP1056775B1 (de) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
JP2002504527A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
NZ511931A (en) 1998-12-07 2004-01-30 Sod Conseils Rech Applic Analogues of glucagon like peptide-1
ES2249933T3 (es) * 1998-12-22 2006-04-01 Eli Lilly And Company Formulacion autoestable de peptido 1 tipo glucagon.
KR100675711B1 (ko) 1999-01-14 2007-02-01 아밀린 파마슈티칼스, 인크. 신규 엑센딘 아고니스트 제제 및 이의 투여 방법
RU2001128068A (ru) 1999-03-17 2004-02-20 Ново Нордиск А/С (DK) Способ ацилирования пептидов и новые ацилирующие агенты
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
ATE264870T1 (de) 2000-01-27 2004-05-15 Lilly Co Eli Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
JP4227894B2 (ja) 2001-08-23 2009-02-18 イーライ リリー アンド カンパニー グルカゴン様ペプチド１アナログ

Also Published As

Publication number Publication date
ES2375056T3 (es) 2012-02-24
CN1812808B (zh) 2012-07-04
CN1812808A (zh) 2006-08-02
EP2292253A2 (de) 2011-03-09
EP2292253A3 (de) 2011-12-14
US20060183682A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE529126T1 (de) Stabilisierte pharmazeutische peptid zusammensetzungen
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
MXPA05013048A (es) Composiciones peptodicas farmaceuticas estabilizadas.
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
PL1633391T3 (pl) Stabilizowane farmaceutycznie kompozycje peptydowe
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
ATE503461T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
ATE407663T1 (de) Azithromycin enthaltende pharmazeutische zusammensetzungen mit verringerten nebenwirkungen
FI20011478L (fi) Farmaseuttinen koostumus
WO2006033700A3 (en) Her2 antibody composition
WO2005044234A3 (en) Nanoparticulate compositions having a peptide as a surface stabilizer
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
IS7051A (is) Lyfjasamsetningar
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
NO20073914L (no) Biologisk aktive peptider
DE50305507D1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
WO2007011878A8 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
NO20052807D0 (no) Fremgangsmate for fremstilling av aminosyrer
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
ATE409032T1 (de) Orodispersible pharmazeutische zusammensetzung einer antithrombotischen verbindung
AU2003238896A1 (en) Stabilized pharmaceutical compositions containing benzimidazole compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties